BR112012008238A2 - métodos para prevenção ou tratamento de sarcopenia e atrofia muscular em animais. - Google Patents

métodos para prevenção ou tratamento de sarcopenia e atrofia muscular em animais.

Info

Publication number
BR112012008238A2
BR112012008238A2 BR112012008238A BR112012008238A BR112012008238A2 BR 112012008238 A2 BR112012008238 A2 BR 112012008238A2 BR 112012008238 A BR112012008238 A BR 112012008238A BR 112012008238 A BR112012008238 A BR 112012008238A BR 112012008238 A2 BR112012008238 A2 BR 112012008238A2
Authority
BR
Brazil
Prior art keywords
animals
methods
muscle atrophy
preventing
treating sarcopenia
Prior art date
Application number
BR112012008238A
Other languages
English (en)
Inventor
Pere-Trepat Emma
Arce Vera Francia
Martin Françoise-Pierre
Collino Sebastiano
André Dominique Rezzi Serge
Kochhar Sunil
Pan Yuanlong
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112012008238A2 publication Critical patent/BR112012008238A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents

Abstract

patente de invenção: método para prevenção ou tratamento de sarcopenia e atrofia muscular em animais. a presente invenção refere-se a métodos para uma ou mais dentre prevenção ou tratamento de sarcopenia e atrofia muscular em animais. os métodos compreendem administrar isoflavonas aos animais, preferivelmente em quantidades de cerca de 0,001 a cerca de 10g/kg/dia.
BR112012008238A 2009-10-09 2010-10-08 métodos para prevenção ou tratamento de sarcopenia e atrofia muscular em animais. BR112012008238A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27863309P 2009-10-09 2009-10-09
PCT/US2010/002722 WO2011043827A1 (en) 2009-10-09 2010-10-08 Methods for preventing or treating sarcopenia and muscle atrophy in animals

Publications (1)

Publication Number Publication Date
BR112012008238A2 true BR112012008238A2 (pt) 2017-06-06

Family

ID=43857050

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008238A BR112012008238A2 (pt) 2009-10-09 2010-10-08 métodos para prevenção ou tratamento de sarcopenia e atrofia muscular em animais.

Country Status (12)

Country Link
US (1) US9301941B2 (pt)
EP (1) EP2485740B1 (pt)
JP (1) JP6122638B2 (pt)
CN (1) CN102573857A (pt)
AU (1) AU2010303872B2 (pt)
BR (1) BR112012008238A2 (pt)
CA (1) CA2776950C (pt)
ES (1) ES2688447T3 (pt)
IN (1) IN2012DN02624A (pt)
MX (1) MX2012004118A (pt)
RU (1) RU2558534C2 (pt)
WO (1) WO2011043827A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
EP3520793B1 (en) 2011-06-06 2023-03-29 University of Iowa Research Foundation Substances and compostions for use in methods of inhibiting muscle atrophy
US9913823B2 (en) * 2011-10-18 2018-03-13 Amorepacific Corporation SIRT 1 activator including syringaresinol
MY194893A (en) * 2014-04-28 2022-12-22 Suntory Holdings Ltd Muscle atrophy inhibitor containing quercetin glycoside
CA2975217C (en) 2015-02-13 2023-08-15 Mars, Incorporated Pet food feeding system
KR20170002846A (ko) 2015-06-30 2017-01-09 (주)아모레퍼시픽 콩잎 추출물을 유효성분으로 함유하는 근질환 억제 및 예방용 조성물
GB201522304D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product for reducing muscle breakdown
CN108635571B (zh) * 2018-07-19 2021-10-22 西安交通大学医学院第一附属医院 鸢尾素(irisin)在制备预防及治疗重症急性胰腺炎药物中的应用
EP4039329A4 (en) * 2019-10-04 2023-08-02 Suntory Holdings Limited COMPOSITION FOR SUPPRESSING LOSS OF MUSCLE MASS, PREVENTING LOSS INSIDE, MAINTAINING, RECOVERING OR ENHANCING ITS INSIDE
KR102623198B1 (ko) * 2020-02-26 2024-01-10 한국 한의학 연구원 돌콩 추출물을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소의 예방, 개선 또는 치료용 조성물
RU2756154C1 (ru) * 2020-11-13 2021-09-28 Митхат Зульфугар-Оглы Гасанов Способ диагностики саркопении у пациентов с хронической болезнью почек 5д стадии, получающих лечение программным гемодиализом
WO2023140407A1 (ko) * 2022-01-21 2023-07-27 경상국립대학교병원 쿠메스트롤을 포함하는 근감소증 예방 또는 치료용 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166380B (pt) 1973-07-09 1975-03-28
US6887499B2 (en) * 2000-05-22 2005-05-03 Enitan A. Bababunmi Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
EP1192943A3 (en) * 2000-09-28 2002-11-27 Pfizer Products Inc. Use of growth hormone secretagogues in conjunction with physical exercise
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
JP5384777B2 (ja) 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
WO2005007676A2 (en) 2003-07-10 2005-01-27 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
JP2007519743A (ja) 2004-01-29 2007-07-19 エリクシアー ファーマシューティカルズ， インコーポレイテッド ウイルス障害の処置
CA2559974C (en) * 2004-03-17 2012-08-14 Nestec S.A. Compositions and methods for reducing or preventing obesity
JP2009537582A (ja) 2006-05-24 2009-10-29 ディーエスエム アイピー アセッツ ビー．ブイ． 有機化合物の新しい用途
JP5345534B2 (ja) * 2006-08-24 2013-11-20 ユニバーシティ オブ テネシー リサーチ ファウンデーション 置換アシルアニリドおよびそれらの使用方法

Also Published As

Publication number Publication date
EP2485740A1 (en) 2012-08-15
AU2010303872A1 (en) 2012-04-19
IN2012DN02624A (pt) 2015-05-22
CA2776950A1 (en) 2011-04-14
ES2688447T3 (es) 2018-11-02
JP2013507361A (ja) 2013-03-04
MX2012004118A (es) 2012-05-08
RU2558534C2 (ru) 2015-08-10
WO2011043827A1 (en) 2011-04-14
US20120238515A1 (en) 2012-09-20
JP6122638B2 (ja) 2017-04-26
EP2485740B1 (en) 2018-08-29
CN102573857A (zh) 2012-07-11
EP2485740A4 (en) 2013-04-03
CA2776950C (en) 2023-11-21
RU2012118686A (ru) 2013-11-20
AU2010303872B2 (en) 2016-06-23
US9301941B2 (en) 2016-04-05

Similar Documents

Publication Publication Date Title
BR112012008238A2 (pt) métodos para prevenção ou tratamento de sarcopenia e atrofia muscular em animais.
WO2018084531A3 (ko) 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
EA201370208A1 (ru) Формы рифаксимина и их применение
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
BR112016029713A2 (pt) métodos para o tratamento de sobrepeso ou obesidade
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
MX2010004074A (es) Combinacion 059.
BR112013013429A2 (pt) composição, método de prevenção ou tratamento de distúrbio ou doença de controle da respiração, e, método de prevenção de desestabilização ou estabilização do ritmo respiratório
WO2008016643A3 (en) Certain chemical entities, compositions, and methods
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
MX359626B (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o afecciones asociadas con disfunción mitocondrial.
TNSN08400A1 (en) Organic compounds and their uses
MX2010001692A (es) Ciertas entidades quimicas, composiciones y metodos.
EA201492279A1 (ru) Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек
BR112014019399A2 (pt) métodos de tratamento da fibrose
MX2015006120A (es) Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos.
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
UA118339C2 (uk) Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)
BR112012009121A2 (pt) Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central
EA201200428A1 (ru) Композиция и способ для лечения ожирения
BRPI0917245A8 (pt) Compostos derivados de isoquinolinona e sua composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL